JAK1 and graft versus host disease: Our findings were confirmed and further expanded upon by the labs of Choi and DiPersio showing similar results using IFN-γ-receptor knock-out donors demonstrating that pharmaceutical targeting of JAK1/2 signaling is highly effective in preventing GVHD while retaining GVL-responses (36, 37).